By BioNanoNet
The in vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Moreover, the group has strong background in oncology and counts with different type of cancer mouse models, all of them monitorable by means of bioluminescence imaging (1). They include subcutaneous models in a great variety of cancer types (prostate, colon, breast, pancreas, kidney, etc.) and also orthtopic and experimental metastasis models. The group can also set-up and validate novel xenograft models upon request (ISO 9001:2008 certified). List of available models: Subcutaneous models (different cell lines and cancer types); Orthotopic models: Intraprostatic, Intramammary (i.m.f.p.), Stereotactic, Ceccum, Intrapulmonar; Experimental metastases: Intracardiac (bone metastases), Intravenous (lung metastases), Intraportal (liver metastases); Spontaneous metastases. Reference publication: (1) Rafael, Diana, et al. “Efficient EFGR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic® F127/Gelatin.” Chemical Engineering Journal (2017).
